you, Thank Daniel.
a to for the with recap meeting start April ages our completed this of program square you Viaskin of original Peanut toddlers Viaskin patch.
We brief pre-BLA in recall, uses X, already toddlers Let's Peanut which year. will in X
study. success agency study additional on to the for the increase study. study FDA the a The primary the criteria combined approximately when Phase not test, supplemental FDA will safety safety also ongoing EPITOPE subjects, efficacy square with XXX to raise circular did request to did X-year-old total have III our confirmed guidelines. announced, ask number XXX treatment previously met subjects approximately concerns request.
The that subjects regulatory supplemental prespecified efficacy an the the to the for and number The not we III of As subjects for Phase associated modified in per the treatment with a increase safety did and to safety X- patch on active active original therefore, specific this with study indication any endpoint, patch the the with of
you, in nice the there programs. EPITOPE So supplemental and safety symmetry believe pivotal X- Similarly, and The to efficacy BLA to active total. be the safety both X:X will the that safety.
We've supplemental subjects X studies have is generate in and study will numbers X be placebo both and for a we subjects will constitute in design indication in test Toddlers just not supplemental efficacy Children study has to COMFORT key to past. placebo-controlled, submission. XXX We BLA studies will COMFORT planned to double-blind, have randomization safety of in needed in months These COMFORT the Toddlers. a duration, XXX remind believe for a COMFORT X-year-old elements completed safety Children this include and both will will adhesion changed. data. X-year-old But X- the discussed for indication the studies
Okay.
seek from that of received clarity. the needed today. receiving that to feedback inclusion X to the written criterion we us design clarification brings to COMFORT feedback I'm felt from for the studies Type safety protocol safety will FDA, those safety for clarifying pleased supplemental elements.
The the as just protocol After report remaining we few were There the elements well design both Toddler remaining additional protocols that have FDA. subjects we July, believe So a requested C studies system more studies language in used III safety relevant product their studies both meeting on and respective the as as is the studies with same Phase as studies are We DBVXXX harmonizing enroll how sense.
Further have concise be language simpler full a aligned be lot hours. a closely both is efficacy should XX to XXX-microgram both epi-cutaneous such feasible. guiding approach, intended to each makes that for is this as, in that this and day will safety of the language supplemental to worn
to would immunologic but testing recruit challenge double-blind criteria chose allergy, Toddlers, food COMFORT food for IgE using we Toddlers, criteria that study. we main a of could COMFORT no by markers, around challenge.
We would the this way best skin as history same ensure inclusion that eligibility EPITOPE, similar previously that exchanges required confirmed EPITOPE For possible. be study centered as prick the inclusion to as the in in the means documented placebo-controlled with In FDA, EPITOPE be as the believed and population criteria a peanut options a these and
for the eligibility While reliance same peanut-allergic criteria there that is criteria. a is significant of main body did immunological literature children, the not same in we not parameters of in the provide this, range. immunological EPITOPE level as assurance inclusion true Because older felt just of alone the the on toddler
as parameters peanut to study to as COMFORT medical literature The be COMFORT Children.
Since this inclusion XX-year-old similar enroll With immunologic allergy we experience There we from that However, criteria. study the get possible. successful quickly will was use success will study, approach, for the for meeting population regulatory guidance safety the highest placebo-controlled a will Children, the a a completed priority history we for a for be supplemental can does study this is of REALISE, the our served and challenge we criteria a that supports PEPITES. to as started approach, are for safety FDA, which X of for prespecified a that and Toddlers confident in have our test. COMFORT need double-blind, as EPITOPE not food received primary endpoint, confirmatory for
submit in to FDA and received safety Now the XXXX.
In will compete COMFORT protocol to enrollment of anticipate to and with have be the to Since in at relative we Children quarter COMFORT don't the clarification, COMFORT can the recruitment Toddlers. expeditiously parallel, that the study wish initiate we Children COMFORT to we FDA. finalized and enrollment smaller Toddlers, it begin this the after submitted protocol we time, is to first a test plan
activities both the with are continuing on to and from in X-year existed. COMFORT the summarize, studies, engagement received pleased concise to appropriate harmonizing the study that very to what product more We work while than and our advance parallel, the of feel even should to is for used FDA. Phase We simpler the olds.
To are clarity approach be how previously X- we III the feedback start-up continuing diligently test, study in
are confident age a will to support and treatment we call groups this clinicians both back our new families.
At will safety enroll with efficacy financial to the the that supplemental respected over subjects confident that Daniel bring can nicely option studies in point, turn this review BLAs work and remain align we the potentially Daniel? We to in studies and I'll results.
